Business Context and Reporting Period
Inhibikase Therapeutics, Inc. (IKT) filed a Form 8-K Current Report on July 29, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC. The report details a specific corporate transaction occurring on the date of the filing.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a securities transaction.
Material Changes
On July 29, 2026, the company entered into an exchange agreement with RA Capital Healthcare Fund, L.P. (RA Capital). Under this agreement:
- RA Capital exchanged 18,030,000 shares of Inhibikase common stock for a pre-funded warrant.
- The pre-funded warrant allows the acquisition of 18,030,000 shares of common stock.
- The exercise price of the warrant is $0.001 per share.
- The warrant is immediately exercisable and has no expiration date.
- The issuance was made without registration under Section 3(a)(9) of the Securities Act of 1933.
Terms, Risks, and Contingencies
The pre-funded warrant includes specific terms and restrictions:
- Beneficial Ownership Blocker: The holder cannot exercise the warrant if doing so would cause their aggregate beneficial ownership to exceed 9.99% of the total issued and outstanding shares. This threshold can be adjusted by the holder with 61 days' prior notice, up to a maximum of 19.99%.
- Adjustments: The number of shares issuable upon exercise is subject to adjustment for corporate events such as stock dividends, splits, and combinations.
- Exhibit Reference: The full terms are detailed in the Form of Pre-Funded Warrant filed as Exhibit 4.1.
Investor Verification Checklist
- Verify the total number of outstanding shares to calculate the exact percentage ownership RA Capital holds post-transaction.
- Review Exhibit 4.1 (Form of Pre-Funded Warrant) for complete legal terms and adjustment mechanisms.
- Confirm the current beneficial ownership status of RA Capital to understand the immediate exercisability limits under the 9.99% blocker.
- Check subsequent filings for any notices regarding the adjustment of the beneficial ownership threshold.